Skip to main content

Advertisement

Table 5 Additional lipid efficiency outcomes following evolocumab treatments stratified by dosages versus placebo at 12-week follow-up

From: Safety and efficacy of anti-PCSK9 antibodies: a meta-analysis of 25 randomized, controlled trials

Endpoints Evolocumab dosages Mean Difference, % (95 % CI) Test for overall effect Number of studies Number of individuals Heterogeneity Publication bias
Z P value Evolocumab Placebo I 2 P value P_Begg P_Egger
TC 420 mg Q4W −36.66 (−38.93, −34.39) 31.60 0.000 6 539 825 38.0 % 0.153 1.000 0.980
140 mg Q2W −40.48 (−45.33, −35.62) 16.35 0.000 4 456 730 85.3 % 0.000 0.734 0.552
HDL-C 420 mg Q4W 7.58 (5.69, 9.46) 7.89 0.000 9 688 1121 23.3 % 0.236 1.000 0.843
140 mg Q2W 6.90 (5.37, 8.43) 8.84 0.000 6 586 993 0.0 % 0.551 0.133 0.030
Non-HDL-C 420 mg Q4W −52.11 (−55.07, −49.14) 34.42 0.000 8 672 1088 57.9 % 0.020 0.618 0.499
140 mg Q2W −56.07 (−61.67, −50.47) 19.62 0.000 6 586 993 89.0 % 0.000 0.452 0.616
TC/HDL-C 420 mg Q4W −41.26 (−45.65, −36.87) 18.43 0.000 6 317 374 64.7 % 0.015 0.566 0.302
140 mg Q2W −44.85 (−49.11, −40.59) 20.64 0.000 4 229 285 63.6 % 0.041 0.089 0.126
VLDL-C 420 mg Q4W −22.75 (−27.46, −18.04) 9.47 0.000 6 567 925 6.6 % 0.374 0.452 0.335
140 mg Q2W −24.83 (−38.29, −11.38) 3.62 0.000 4 480 831 82.3 % 0.001 0.734 0.462
ApoB 420 mg Q4W −45.14 (−49.16, −41.12) 22.00 0.000 9 688 1121 78.8 % 0.000 0.076 0.027
140 mg Q2W −52.69 (−57.40, −47.98) 21.91 0.000 6 586 993 85.6 % 0.000 0.707 0.450
ApoA1 420 mg Q4W 5.17 (2.60, 7.73) 3.95 0.000 6 317 374 40.6 % 0.135 0.566 0.517
140 mg Q2W 6.26 (1.71, 10.82) 2.69 0.007 4 230 285 74.5 % 0.008 0.308 0.129
ApoB/ApoA1 420 mg Q4W −48.06 (−52.70, −43.43) 20.32 0.000 7 395 527 72.4 % 0.001 0.649 0.351
140 mg Q2W −53.68 (−57.77, −49.59) 25.74 0.000 5 305 438 65.8 % 0.020 0.806 0.500
TG 420 mg Q4W −15.70 (−20.35, −11.05) 6.62 0.000 9 688 1121 42.5 % 0.084 0.118 0.030
140 mg Q2W −17.35 (−23.50, −11.20) 5.53 0.000 6 586 993 59.8 % 0.029 1.000 0.039
Lp(a) 420 mg Q4W −25.40 (−29.09, −21.70) 13.47 0.000 9 688 1121 47.1 % 0.057 1.000 0.626
140 mg Q2W −32.39 (−38.92, −25.87) 9.73 0.000 6 586 993 79.3 % 0.000 1.000 0.819
PCSK9 420 mg Q4W −44.04 (−53.90, −34.17) 8.75 0.000 6 540 908 85.2 % 0.000 0.452 0.473
140 mg Q2W −60.92 (−83.94, −37.89) 5.18 0.000 2 132 188 92.9 % 0.000 1.000 NA
  1. ApoA1, apolipoprotein A1; ApoB, apolipoprotein B; ApoB/ApoA1, ratio of ApoB/ApoA1; CI, confidence interval; HDL-C, high-density lipoprotein (HDL) cholesterol; Lp(a), lipoprotein(a); NA, not applicable; Non-HDL-C, non-HDL cholesterol; PCSK9, proprotein convertase subtilisin/kexin type 9; TC, total cholesterol; TC/HDL-C, ratio of total cholesterol/HDL cholesterol; TG, triglycerides; VLDL-C, very low-density lipoprotein (VLDL) cholesterol